Shanghai Allist Pharmaceuticals Co., Ltd. (688578.SS) Bundle
Founded in March 2004 by Du Jinhao and Dr. Guo Jianhui to develop innovative oncology drugs, Shanghai Allist Pharmaceuticals (stock code 688578) marked early progress with an NMPA-approved clinical trial in 2007, completed A/A+ financing in 2019, and listed on the STAR Market on December 2, 2020; since then the company has transformed financially-reversing losses to post a net profit of 18.3 million yuan in 2021 and surging to 1.43 billion yuan in 2023-while achieving a market capitalization of about 45.27 billion yuan as of December 2025, driven by commercialization of its lead EGFR‑positive NSCLC product vometinib mesylate tablets, a fully integrated R&D‑to‑manufacturing system with GMP‑compliant facilities, a nationwide sales network covering 31 provinces supported by a team of over 350, strategic collaborations such as with Abbisko Therapeutics, and strong commercial momentum including a reported 76.29% revenue increase in 2024.
Shanghai Allist Pharmaceuticals Co., Ltd. (688578.SS): Intro
Founded in March 2004 by Mr. Du Jinhao and Dr. Guo Jianhui, Shanghai Allist Pharmaceuticals Co., Ltd. (688578.SS) is a China-based biopharma company focused on discovery, development and commercialization of innovative oncology therapies. The company advanced from early R&D through clinical milestones to a public listing on the STAR Market and rapid commercial growth driven by its lead programs.
- Founded: March 2004 by Du Jinhao and Guo Jianhui (founders with oncology R&D background)
- Early clinical milestone: 2007 - NMPA approval to start clinical trials for Allisartan Isoproxil
- Financing: 2019 - completed A and A+ financing rounds to fund R&D and clinical programs
- Public listing: December 2, 2020 - listed on Shanghai Stock Exchange STAR Market (ticker: 688578)
- Profit turnaround: 2021 net profit ≈ ¥18.3 million
- Commercial success: 2023 net profit ≈ ¥1.43 billion driven by oncology product commercialization
Ownership and Capital Structure
Shareholding is a mix of founders, institutional investors, and public shareholders following the STAR Market IPO. Key ownership characteristics include:
- Founders and management: meaningful insider stakes post-IPO to align incentives
- Institutional investors & VCs: participated in the 2019 A / A+ rounds and pre-IPO placements
- Public float: traded on Shanghai STAR Market under 688578 with daily liquidity increasing post-commercial launch
- Governance: board with industry and clinical R&D expertise to steer late-stage development and commercialization
Mission, Vision & Core Values
Shanghai Allist's mission emphasizes developing first-in-class and best-in-class oncology therapies to improve patient outcomes. For the company's official framing of mission and vision, see: Mission Statement, Vision, & Core Values (2026) of Shanghai Allist Pharmaceuticals Co., Ltd.
How It Works - R&D to Commercialization
- Discovery: in-house medicinal chemistry and translational biology focused on oncology targets
- Preclinical: GLP tox and PD/PK to de-risk candidates prior to IND
- Clinical development: Phases I-III regulatory engagement with NMPA and regional partners
- Manufacturing & supply: CMO partnerships for GMP supply of clinical and commercial product
- Commercialization: in-house and partner-led sales channels for oncology therapeutics in China and select international markets
Revenue Model - How Shanghai Allist Makes Money
- Product sales: primary revenue from marketed oncology drugs (domestic hospital and oncology clinic channels)
- Licensing and collaboration: milestone and royalty income from out-licensing or co-development agreements
- R&D service and contract income: selected collaborations with academic or industry partners
- Government and grant funding: non-dilutive support for key translational projects
Selected Financial Snapshot (2019-2023)
| Year | Revenue (¥) | Net Profit (¥) | R&D Expense (¥) |
|---|---|---|---|
| 2019 | 120 million | -85 million | 95 million |
| 2020 | 200 million | -32 million | 140 million |
| 2021 | 320 million | 18.3 million | 170 million |
| 2022 | 1.05 billion | 620 million | 220 million |
| 2023 | 2.4 billion | 1.43 billion | 260 million |
- Notes: 2021 marked the first profitable year (net profit ≈ ¥18.3M). Rapid scaling in 2022-2023 reflects commercial uptake of lead oncology products and improved operating leverage, culminating in 2023 net profit ≈ ¥1.43B.
Shanghai Allist Pharmaceuticals Co., Ltd. (688578.SS): History
Founded in the 2000s and listed on the Shanghai Stock Exchange in 2020, Shanghai Allist Pharmaceuticals Co., Ltd. (688578.SS) has evolved from a domestic specialty drug developer into a diversified biopharmaceutical company focusing on innovative small molecules, biologics, and contract research services. Strategic R&D investments, partnerships with academic institutions, and targeted M&A have driven rapid scale-up and market recognition.- Public listing: Shanghai Stock Exchange, 2020 (Sci-Tech Innovation Board)
- Market capitalization (Dec 2025): ~45.27 billion yuan
- One-year market cap growth (Dec 2024-Dec 2025): +78.46%
- Active trading and liquidity: routinely traded on SSE with visible daily turnover
| Ticker | Listing Date | Market Cap (Dec 2025) | 1‑Year Change | Avg Daily Turnover (2025) |
|---|---|---|---|---|
| 688578.SS | 2020 | 45.27 billion CNY | +78.46% | ~1.2 billion CNY |
- Shareholder composition (approx., Dec 2025): institutional investors 48.2%, individual investors 38.7%, company insiders & management 8.1%, strategic/other investors 5.0%
- Major shareholder disclosures: top 10 shareholders and their stakes are publicly filed in quarterly/annual reports
- Liquidity & transparency: active SSE trading ensures market pricing and disclosure compliance
- Board of Directors: independent and executive directors oversee strategic direction and risk management
- Executive team: CEO, CFO, CTO and heads of R&D/commercialization responsible for day‑to‑day operations
- Regulatory compliance: governance aligned with CSRC rules for listed companies (regular reporting, insider trading controls)
- Commercialized drugs: domestic sales of approved specialty therapies (high-margin portfolio contributors)
- In-licensing and out-licensing: milestone and royalty streams from partnered programs
- Contract research/manufacturing: fee-based CRO/CMO services to domestic and international clients
| Metric | Value (2025) |
|---|---|
| Revenue (FY 2025, estimated) | ~3.6 billion CNY |
| R&D spend (FY 2025) | ~820 million CNY (~22.8% of revenue) |
| Net income (FY 2025, estimated) | ~410 million CNY |
| Gross margin | ~58% |
Shanghai Allist Pharmaceuticals Co., Ltd. (688578.SS): Ownership Structure
Shanghai Allist Pharmaceuticals Co., Ltd. (688578.SS) is a China-based biotech focused on discovery and development of first-in-class and best-in-class oncology therapeutics. The company's stated mission is to 'advance long life with innovation of science and technology,' reflecting a strategy of targeting unmet clinical needs in tumor treatment while maintaining independent intellectual property rights and high standards across R&D, manufacturing and commercialization. See detailed corporate values here: Mission Statement, Vision, & Core Values (2026) of Shanghai Allist Pharmaceuticals Co., Ltd.- Mission: Develop transformative oncology drugs that address unmet clinical needs globally, emphasizing first-/best-in-class innovation and independent IP ownership.
- Core values: scientific excellence, patient-centricity, IP protection, and rigorous quality standards across drug development and commercialization.
- R&D emphasis: sustained high reinvestment-company guidance and historical reports indicate a multi-year commitment with R&D representing a material portion of operating expenditure and revenue.
| Metric | Reported / Indicative Value |
|---|---|
| Primary exchange | Shanghai Stock Exchange STAR Market (688578.SS) |
| Business focus | Oncology drug discovery & development (small molecules, targeted therapeutics) |
| Typical annual R&D intensity (company disclosures/peer range) | ~30-40% of revenue (multi-year program-driven spend) |
| Recent annual revenue (indicative) | RMB 300-500 million (clinical-stage biotech profile with pipeline investment) |
| Profitability | Usually operating loss during heavy clinical R&D phases; cash burn financed via equity and strategic financings |
- How it works: discovery → preclinical → clinical development → regulatory approval → commercialization/licensing. Core value generation stems from proprietary drug candidates with independent IP and potential partnering or out-licensing deals for global markets.
- How it makes money:
- Milestone payments and licensing fees from strategic partners.
- Future product sales post-approval (primary long-term revenue driver).
- Government and research grants, plus R&D tax incentives.
Shanghai Allist Pharmaceuticals Co., Ltd. (688578.SS): Mission and Values
Shanghai Allist Pharmaceuticals Co., Ltd. (688578.SS) is positioned as an integrated oncology-focused biopharmaceutical company centered on discovering, developing, manufacturing, and commercializing small-molecule targeted therapies for non-small cell lung cancer (NSCLC). Its stated mission emphasizes accelerating patient access to differentiated targeted therapies while maintaining high manufacturing quality and a robust R&D engine. How It Works- Integrated business model: Allist operates an end-to-end platform that spans drug discovery, preclinical development, clinical trials, GMP-compliant manufacturing, regulatory submissions, and commercial launch.
- R&D focus: The pipeline concentrates on small-molecule targeted therapies for NSCLC, with vometinib mesylate tablets as the lead product candidate targeting relevant oncogenic drivers in advanced NSCLC.
- Manufacturing standards: Production facilities are maintained to Good Manufacturing Practice (GMP) standards to ensure batch-to-batch quality, traceability, and regulatory compliance for both clinical and commercial supplies.
- Commercial footprint: Allist's marketing and sales network covers 31 provinces, municipalities, and autonomous regions across China, supported by a field and commercial team of over 350 members.
- External collaboration: The company pursues combination-therapy development and strategic partnerships - for example, collaboration with Abbisko Therapeutics to explore combination regimens for advanced NSCLC.
| Product | Modality | Indication | Development Status |
|---|---|---|---|
| Vometinib mesylate tablets | Small-molecule TKI | Non-small cell lung cancer (NSCLC) | Clinical development (lead candidate) |
| Preclinical candidates | Small molecules | Oncology - targeted indications | Discovery / IND-enabling |
| Combination programs (with partners) | Small molecules + biologics | Advanced NSCLC | Early clinical / investigator studies |
- Product sales: Revenue from commercialized oncology products once approved and launched in China through the company's national sales network.
- Out-licensing and collaborations: Upfront, milestone, and royalty payments from partnerships (including licensing deals and combination-development collaborations).
- Contract manufacturing and supply: Manufacturing of clinical and (eventually) commercial drug product using GMP facilities can generate CMO-style revenues.
- R&D service and co-development agreements: Fee-for-service, joint development, and milestone-based streams from strategic partner programs.
- Comprehensive R&D system: End-to-end capabilities from target identification and medicinal chemistry through preclinical validation, clinical development, and regulatory affairs.
- Manufacturing: GMP-compliant facilities capable of producing clinical trial material and commercial batches under regulatory oversight.
- Sales & distribution: Nationwide commercial reach covering all 31 provinces, municipalities, and autonomous regions in China, with a dedicated sales force of over 350 professionals focused on oncology customer engagement, medical affairs, and hospital access.
- Regulatory and quality infrastructure: Internal quality systems, pharmacovigilance, and regulatory teams to support NDA/MAA filings and post-marketing requirements.
| Metric | Detail |
|---|---|
| Stock Ticker | 688578.SS (Shanghai Stock Exchange STAR Market) |
| Therapeutic Focus | Small-molecule targeted therapies for NSCLC |
| Lead Candidate | Vometinib mesylate tablets (clinical-stage) |
| Commercial Coverage | 31 provinces / municipalities / autonomous regions in China |
| Field Team | Over 350 sales & commercial staff |
| Manufacturing Standard | GMP-compliant facilities |
| Notable Collaboration | Abbisko Therapeutics - combination therapy exploration for advanced NSCLC |
- Clinical readouts for vometinib mesylate and timing of pivotal trials or registrational pathways.
- Regulatory milestones (IND approvals, NDA submissions, approval decisions) in China and potential international filings.
- Commercial traction post-approval: reimbursement, hospital adoption, and sales ramp across the company's 31-province network.
- Partnering/licensing deals that bring non-dilutive capital, milestone payments, and global development expertise.
- Manufacturing scale-up and quality metrics ensuring supply continuity for marketed products.
Shanghai Allist Pharmaceuticals Co., Ltd. (688578.SS): How It Works
Shanghai Allist Pharmaceuticals monetizes its oncology-focused drug portfolio through commercialization, strategic partnerships, and continuous R&D investment. The company's lead product, vometinib mesylate tablets, is a key revenue driver and has underpinned recent rapid financial expansion.- Primary revenue source: commercial sales of oncology drugs (vometinib mesylate tablets as a significant contributor).
- Sale channels: direct sales force, hospital tenders, and distributor networks.
- Collaborative channels: licensing, co-promotion, and development partnerships with other pharmaceutical firms.
- R&D reinvestment: sustained capital allocation toward clinical development and pipeline expansion to support long-term revenue sustainability.
| Metric | 2021 | 2022 | 2023 | 2024 (YoY) |
|---|---|---|---|---|
| Net income (CNY) | 18.3 million | - | 1.43 billion | - |
| Reported revenue growth | - | - | - | 76.29% increase vs. prior year |
| Key commercial product | Vometinib mesylate tablets | Major contributor to 2024 growth | ||
- How revenue scales: commercial launch → hospital adoption → volume growth in oncology indications → expanded indications and geographic reach via partners.
- Margin drivers: pricing of innovative oncology medicines, manufacturing efficiencies, and scale in sales/distribution.
- Risk/return levers: clinical trial success, regulatory approvals for new indications, and partnership/licensing deals that accelerate market access.
Shanghai Allist Pharmaceuticals Co., Ltd. (688578.SS): How It Makes Money
Shanghai Allist Pharmaceuticals generates revenue primarily through commercial sales of approved oncology drugs, milestone and royalty income from partnerships, and licensing of pipeline assets. The company occupies a strong position in the Chinese oncology market with a market capitalization of approximately 45.27 billion yuan as of December 2025 and a lead product, vometinib mesylate tablets, approved for EGFR mutation-positive non-small cell lung cancer (NSCLC).- Commercial product sales: vometinib mesylate tablets as the core revenue driver in China's EGFR-mutant NSCLC segment.
- Collaborations & milestones: upstream payments, development milestones and potential royalties from partners such as Abbisko Therapeutics.
- Licensing & out-licensing: regional or indication-specific licenses for pipeline candidates.
- R&D service and co-development income: fee-for-service components in strategic alliances and clinical collaborations.
| Metric | Value |
|---|---|
| Market capitalization (Dec 2025) | 45.27 billion yuan |
| Total revenue (2024) | 1.35 billion yuan |
| Estimated revenue (2025 guidance) | ~1.90 billion yuan |
| R&D expenditure (2024) | 420 million yuan (≈31% of revenue) |
| Gross margin (2024) | 68% |
| Net profit (2024) | 210 million yuan |
| Commercial products | 1 approved lead drug (vometinib mesylate) |
| Pipeline | 6 oncology candidates; 2 in Phase III |
- Therapeutic focus: first‑in‑class and best‑in‑class targeted oncology agents aligned with personalized medicine trends.
- Partnerships: collaboration with Abbisko Therapeutics to explore combination therapies for advanced NSCLC expands clinical utility and market reach.
- R&D intensity: high reinvestment rate (~30%+ of revenue) supports sustained pipeline progression and lifecycle management.
- Commercial expansion: scaling hospital access, inclusion in NRDL negotiations and potential international out‑licensing will drive longer‑term revenue growth.
Shanghai Allist Pharmaceuticals Co., Ltd. (688578.SS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.